Journal of Clinical OncologyGenomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report from an International Consortium

Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent rhabdomyosarcoma – the most common soft tissue sarcoma of childhood – remains poor, and beyond PAX-FOX01 fusion status, no genomic markers are available for risk stratification. This international consortium study was designed to determine the incidence of driver mutations and their association with clinical outcome.